Business
CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)
CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.).
About this update from Skylight Health Group Inc.
[{"type":"text","content":"\n Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused on patients with anxietyAnnouncement follows the passage of the 2018 US Farm Bill which legalized the mass production of hemp, a form of cannabis with lower THC levels than marijuana, across the United StatesPartnership follows the request by the US Food and Drug Administration (FDA) for more clinical data to support the safety and efficacy of hemp-based CBD products within medical treatmentsCB2 Insights previously announced partnership to serve as exclusive research technology platform for large UK-based medical cannabis pilot TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that it will begin a prospective trial with GL Brands (OTCQB: FRLF) through its U.S.-based hemp brand and key operating subsidiary, Green Lotus.  The study will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety. “We are proud to have been approached by GL Brands to help advance their product research and development efforts using our vast network of clinical sites and knowledge and experience in conducting clinical trials,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “Cannabis licensed producers, product manufacturers and cannabis-focused pharmaceutical companies have all matured to the point of needing clinically-driven research to support the registration of their medical products.  Our tools and experience help formalize and expedite that process in a way that is aligned with traditional pharmaceutical products.” Patients and Clinicians will be recruited for the study through the existing CB2 Insights clinical network which represents the largest medical cannabis patient registry in the US.  This ability to leverage CB2 Insights as a central source of patient recruitment for trials in an expedited manner helps generate measurable results in a more time-efficient manner; reducing the time needed to validate products that are being brought to market across a v...